VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced the appointment of Thomas D. Szucs, MD, as Chairman of the Supervisory Board. He succeeds Thomas Hecht, MD, whose mandate ended in June 2020.

Press inquiries should be adressed to: